Back to search
FDAFDA · Food and drugs·Recall number D-0233-2024

4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous Use, Rx Only, 10 mL Syringe per Carton, Hospira, Inc., Lake Forst, IL 60045, NDC 0409-5534-24 (carton), 0409-5534-14 (case).

Published January 24, 2024 · Recall initiated: December 21, 2023

Summary

FDA records drug Class I recall D-0233-2024, published January 24, 2024 and initiated December 21, 2023. Recalling firm: Pfizer Inc.; Status: Ongoing; Reported quantity: 34000 Cartons; Lot: Lot GX1542, Exp. 01/01/2025. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter; identified as glass

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pfizer Inc.
Distributor
Nationwide in the USA and Puerto Rico.
Lot
Lot GX1542, Exp. 01/01/2025
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous Use, Rx Only, 10 mL Syringe per Carton, Hospira, Inc., Lake Forst, IL 60045, NDC 0409-5534-24 (carton), 0409-5534-14 (case). recalled?

Yes. FDA published recall D-0233-2024 on January 24, 2024. Reported hazard: Presence of Particulate Matter; identified as glass

What should I do if I have this product?

Voluntary: Firm initiated · Letter